The law, slated to take effect in September, requires health plans to cover the treatment given by in-network providers, not ...

Using 400 real-world patient cases, the CARE platform correctly classified 99.5 percent of cases according to NCCN guidelines ...

NEW YORK – The US Food and Drug Administration on Wednesday granted accelerated approval to Dizal's oral EGFR inhibitor Zegfrovy (sunvozertinib) as a treatment for patients with locally advanced or ...

The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.

D Molecular Therapeutics said it is streamlining operations to offset expected expenses as it accelerates the timelines for its Phase III trials.

The study will use a companion lipid biomarker test to identify those with a poor prognosis who are potential best responders.

The study also included older children and found the best outcomes in patients between 5 years and 8 years old.

NEW YORK – Iksuda Therapeutics on Monday said it will expand an ongoing Phase I trial of the HER2-targeted antibody-drug conjugate (ADC) IKS014 in solid tumors to US sites. The Newcastle, ...

The firm hopes that ETX-636's dual mechanism inhibiting mutant PI3Kα will give it an edge over competing products on the market.

At a subsequent visit, the patient's maternal-fetal medicine doctor reviewed the NIPT result and wrote in consult notes that the laboratory didn't recommend retesting. The doctor also acknowledged in ...

The biotech has received written agreement from the agency through the START pilot program on key aspects of its trial design for evaluating NGN-401.

NEW YORK – Rutgers New Jersey Medical School has rolled out blood testing for lipoprotein (a), a biomarker associated with cardiovascular disease risk, as part of routine care at another hospital site ...